Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK1 Y654F |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK1 Inhibitor JAK1 Inhibitor - ATP competitive |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK1 Y654F | Sezary's disease | sensitive | JAK Inhibitor (Pan) - ATP competitive | Pyridone 6 | Preclinical - Cell culture | Actionable | In a preclinical study, Pyridone 6 (CMP6) inhibited proliferation of cells derived from a Sezary syndrome patient harboring JAK1 Y654F in culture (PMID: 26415585). | 26415585 |
JAK1 Y654F | Sezary's disease | sensitive | JAK1 Inhibitor - ATP competitive | Ruxolitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited growth of primary cells derived from a Sezary syndrome patient harboring JAK1 Y654F in culture (PMID: 26415585). | 26415585 |